This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (50)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Rheumatology  • Rheumatology, Other  • Immunology  • Immunology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Philip J. Hashkes, MD, MSc; Ronald M. Laxer, MD, FRCPC

JAMA. 2005;294:1671-1684.

Context  The treatment of juvenile idiopathic arthritis (JIA) has changed markedly in the last 15 years. Many children with JIA are not treated by pediatric rheumatologists.

Objective  To review the best evidence for the treatment of JIA.

Data Sources  English-language trials of JIA between 1966 and 2005 were searched using MEDLINE, EMBASE, the Cochrane database, and abstracts from recent rheumatology and pediatric scientific meetings.

Study Selection  Randomized controlled trials and open studies including at least 10 patients for medications without controlled trials.

Data Extraction  For studies after 1997, the American College of Rheumatology Pediatric 30 outcome measure was used to define patients as responders. For older studies, the primary response outcome measure defined by the authors was used.

Data Synthesis  Thirty-four controlled studies were identified. Nonsteroidal anti-inflammatory drugs are effective only for a minority of patients, mainly those with oligoarthritis. Intra-articular corticosteroid injections are very effective for oligoarthritis. Methotrexate is effective for the treatment of extended oligoarthritis and polyarthritis and less effective for systemic arthritis. Sulfasalazine and leflunomide may be alternatives to methotrexate. Antitumor necrosis factor medications are highly effective for polyarticular course JIA not responsive to methotrexate but are less effective in systemic arthritis. There is a lack of evidence for the optimal treatment of systemic and enthesitis-related arthritis.

Conclusions  Despite many advances in the treatment of JIA, there is still a lack of evidence for treatment of several disease subtypes. The treatment plan needs to be individualized based on the JIA subtype.

Author Affiliations: Section of Pediatric Rheumatology, Department of Rheumatic Diseases, Cleveland Clinic Foundation, Cleveland, Ohio (Dr Hashkes); Department of Clinical and Academic Affairs, The Hospital for Sick Children and Department of Pediatrics and Medicine, The University of Toronto, Toronto, Ontario (Dr Laxer).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Juvenile Idiopathic Arthritis
Sarah Ringold, Alison Burke, and Richard M. Glass
JAMA. 2005;294(13):1722.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Disease activity and disability in children with juvenile idiopathic arthritis one year following presentation to paediatric rheumatology. Results from the Childhood Arthritis Prospective Study
Hyrich et al.
Rheumatology (Oxford) 2010;49:116-122.
ABSTRACT | FULL TEXT  

New advances in the management of juvenile idiopathic arthritis--1: Non-biological therapy
Beresford and Baildam
EDUCATION AND PRACTICE 2009;94:144-150.
ABSTRACT | FULL TEXT  

Successful treatment with B-cell depleting therapy for refractory systemic onset juvenile idiopathic arthritis: a case report
Kasher-Meron et al.
Rheumatology (Oxford) 2009;48:445-446.
FULL TEXT  

Persistent Elevation of Fibrin D-Dimer Predicts Longterm Outcome in Systemic Juvenile Idiopathic Arthritis
BLOOM et al.
The Journal of Rheumatology 2009;36:422-426.
ABSTRACT | FULL TEXT  

Pharmacotherapy of Juvenile Idiopathic Arthritis
Bell
Journal of Pharmacy Practice 2009;22:17-28.
ABSTRACT  

Abnormal expression of the genes involved in cytokine networks and mitochondrial function in systemic juvenile idiopathic arthritis identified by DNA microarray analysis
Ishikawa et al.
Ann Rheum Dis 2009;68:264-272.
ABSTRACT | FULL TEXT  

A longitudinal analysis of physical functional disability over the course of juvenile idiopathic arthritis
Magni-Manzoni et al.
Ann Rheum Dis 2008;67:1159-1164.
ABSTRACT | FULL TEXT  

Costing juvenile idiopathic arthritis: examining patient-based costs during the first year after diagnosis
Thornton et al.
Rheumatology (Oxford) 2008;47:985-990.
ABSTRACT | FULL TEXT  

Association between duration of symptoms and severity of disease at first presentation to paediatric rheumatology: results from the Childhood Arthritis Prospective Study
Adib et al.
Rheumatology (Oxford) 2008;47:991-995.
ABSTRACT | FULL TEXT  

Quality of randomized clinical trials in juvenile idiopathic arthritis
Abrahamyan et al.
Rheumatology (Oxford) 2008;47:640-645.
ABSTRACT | FULL TEXT  

Improving the evidence base for treatment of juvenile idiopathic arthritis: the challenge and opportunity facing the MCRN/ARC Paediatric Rheumatology Clinical Studies Group
Thornton et al.
Rheumatology (Oxford) 2008;47:563-566.
FULL TEXT  

Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment
van Rossum et al.
Ann Rheum Dis 2007;66:1518-1524.
ABSTRACT | FULL TEXT  

Synovectomy of the Hip in Patients with Juvenile Rheumatoid Arthritis
Carl et al.
JBJS 2007;89:1986-1992.
ABSTRACT | FULL TEXT  

IL1 and TNF gene polymorphisms in patients with juvenile idiopathic arthritis treated with TNF inhibitors
Cimaz et al.
Ann Rheum Dis 2007;66:900-904.
ABSTRACT | FULL TEXT